0
Signin
countryflagUS

18889881171

AAPL 172.82 2.0791% MSFT 398.0952 0.7989% GOOG 168.0231 1.4816% GOOGL 166.28 1.4769% AMZN 184.96 3.3296% NVDA 854.77 2.9335% META 443.315 0.9392% TSLA 181.475 0.825% TSM 136.525 1.1746% LLY 758.37 -2.3663% V 268.64 0.4938% AVGO 1234.73 -0.6541% JPM 191.62 -0.1251% UNH 493.04 1.8446% NVO 125.14 -3.1499% WMT 59.8 1.6143% LVMUY 165.05 0.628% XOM 116.34 0.2672% LVMHF 824.35 0.2456% MA 441.05 -0.2307%

Rallybio Corp

Healthcare US RLYB

1.815USD
-0.085(4.47%)

Last update at 2024-05-02T18:54:00Z

Day Range

1.811.90
LowHigh

52 Week Range

1.729.88
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -65.57900M -45.50800M -24.94000M -17.46000M
Minority interest - - - -
Net income -66.48700M -47.01000M -24.92500M -17.62600M
Selling general administrative 27.20M 18.74M 7.67M 6.28M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 0.17M 0.11M 0.06M 0.03M
Ebit -67.88400M -45.64800M -25.30300M -17.64200M
Ebitda -65.57900M -45.49800M -24.82900M -17.39500M
Depreciation and amortization 2.31M 0.15M 0.47M 0.25M
Non operating income net other 1.02M -1.35500M - -
Operating income -67.88400M -45.64800M -25.30300M -17.64200M
Other operating expenses 67.88M 45.65M 25.30M 17.64M
Interest expense 2.31M 0.01000M 0.05M 0.04M
Tax provision - 0.00000M -0.01500M 0.00000M
Interest income 1.96M 0.05M 0.17M 0.20M
Net interest income 1.96M 0.04M 0.12M 0.16M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.91M 1.50M -0.01500M 0.17M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 67.88M 45.65M 25.30M 17.64M
Cost of revenue - - - -
Total other income expense net 2.31M 0.14M 0.36M 0.18M
Discontinued operations - - - -
Net income from continuing ops -65.57900M -45.50800M -26.44700M -17.56300M
Net income applicable to common shares -66.65400M -45.50800M -26.44700M -17.56300M
Preferred stock and other adjustments - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 180.44M 182.19M 141.86M 21.61M
Intangible assets - - - -
Earning assets - - - -
Other current assets 1.05M 5.54M 1.03M 1.46M
Total liab 11.12M 6.58M 187.88M 41.89M
Total stockholder equity 169.32M 175.60M -47.01400M -20.56700M
Deferred long term liab - - - -
Other current liab 9.45M 5.95M 4.26M 2.95M
Common stock 0.00400M 0.00300M 0.45M 0.23M
Capital stock 0.00400M 0.00300M - -
Retained earnings -160.68100M -94.02700M -47.01400M -20.56700M
Other liab - 0.03M 0.01M 0.94M
Good will - - - -
Other assets - 182.19M - -
Cash 56.96M 175.33M 140.23M 19.46M
Cash and equivalents - - - -
Total current liabilities 10.74M 6.55M 5.84M 3.81M
Current deferred revenue - - - -
Net debt -56.40300M -175.33400M -140.23300M -19.45800M
Short term debt 0.18M - - -
Short long term debt - - - -
Short long term debt total 0.56M - - -
Other stockholder equity 330.21M 269.63M 47.01M 20.57M
Property plant equipment 0.39M 0.51M 0.29M 0.20M
Total current assets 179.50M 180.87M 141.26M 20.92M
Long term investments 0.03M 0.81M 0.31M 0.49M
Net tangible assets 169.32M 175.60M -46.02400M -20.28100M
Short term investments 112.04M - - -
Net receivables - - - -
Long term debt - - - -
Inventory - - - -
Accounts payable 1.11M 0.60M 1.58M 0.86M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.21400M - - -
Additional paid in capital - - - -
Common stock total equity 0.00400M 0.00300M - -
Preferred stock total equity - - - -
Retained earnings total equity -160.68100M -94.02700M - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.03M 0.81M - -
Deferred long term asset charges - - - -
Non current assets total 0.94M 1.32M 0.60M 0.69M
Capital lease obligations 0.56M - - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -112.11600M -2.00000M -1.93500M -1.93500M
Change to liabilities 3.71M 0.73M 0.72M 0.73M
Total cashflows from investing activities -112.17000M -2.33300M -2.07200M -0.18800M
Net borrowings - - - -
Total cash from financing activities 51.08M 82.97M 144.89M 31.57M
Change to operating activities -1.42300M -2.80300M 1.40M 1.34M
Net income -66.65400M -47.01300M -26.44700M -17.56300M
Change in cash -118.37600M 35.10M 120.78M 16.35M
Begin period cash flow 175.33M 140.23M 19.46M 3.10M
End period cash flow 56.96M 175.33M 140.23M 19.46M
Total cash from operating activities -57.28400M -45.53300M -22.03900M -15.02600M
Issuance of capital stock 51.53M 86.20M 145.21M 31.60M
Depreciation 0.17M 0.11M 0.06M 0.03M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 0.22M 82.97M - -
Other cashflows from financing activities -0.67200M -3.23300M -0.31900M -0.03300M
Change to netincome 10.57M 3.65M 2.23M 0.44M
Capital expenditures 0.05M 0.33M 0.14M 0.19M
Change receivables - - - -
Cash flows other operating -4.64500M -3.00200M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -118.37600M 35.10M - -
Change in working capital -0.93600M -3.77900M 2.12M 2.07M
Stock based compensation 9.50M 3.65M 0.70M 0.19M
Other non cash items 0.64M 1.50M 1.52M 0.14M
Free cash flow -57.33800M -45.86600M -22.17600M -15.21400M

Fundamentals

  • Previous Close 1.90
  • Market Cap99.78M
  • Volume90347
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-74.75800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.79

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
RLYB
Rallybio Corp		 -0.085 4.47% 1.81 - - - 0.89 0.25
NVO
Novo Nordisk A/S		 -4.07 3.15% 125.14 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.85 1.46% 128.30 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.13 0.28% 401.01 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 1.62 1.82% 90.76 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Rallybio Corp

234 Church Street, New Haven, CT, United States, 06510

Key Executives

Name Title Year Born
Dr. Martin W. MacKay Ph.D. Co-Founder, CEO & Chairman 1956
Dr. Stephen Uden M.B, M.D. Co- Founder, Pres, COO & Chief Scientific Officer 1958
Mr. Jeffrey M. Fryer CPA Co-Founder, CFO & Treasurer 1970
Ms. Ami Bavishi Head of Investor Relations & Corp. Communications NA
Dr. Steven W. Ryder F.A.C.P, M.D. Chief Medical Officer 1951

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).